Guggenheim Build America Bonds Managed Stock News

Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust offers exposure to taxable municipal bonds and has a primary objective of providing current income. GBAB has seen strong performance in

Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust offers exposure to taxable municipal bonds and other IG and high yield credit products. GBAB has struggled and experienced negative retu

The Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust is a high-duration municipal bond fund that suffered heavy losses in 2022 as interest rates rose. Long-term interest rates are still

I saw some value in GBAB a year ago, but that thesis did not pan out. With 2023 off to a rocky start, I think caution is warranted here. The fund's diversity is a plus, but it brings about risk with h

16 out of 23 CEF sectors positive on price and 12 out of 23 sectors positive on NAV last week. Watch for overvalued CEFs as market volatility rises.

Average coupon or interest rate earned on investments of GBAB is 5.46 percent while it pays dividend with an average yield in excess of 7 percent. Historical price performance of GBAB has been extreme

GBAB has been falling steadily, but a bottom could be at hand.

NBB: Mixed Outlook For The Year Ahead

GBAB traded at a fairly steep premium during my last review, and that made me cautious on the fund. After a sell-off, the fund has a more reasonable valuation, and I continue to find its diversified h

The taxable municipal bond market is growing and mature. Taxable munis offer a range of benefits for certain investors, in particular insurance companies.

GBAB: I Like The Diversity, But The Upside Is Capped

CEF Report April 2021: A Complete Round Trip

In this report, we discuss what's happening in the CEF world in terms of valuations which are nearing the tightest levels of the last five years. Investors have a choice. They can be buy-and-hold inve

GBAB is a great long-term performer with high-quality characteristics. The fund is up over 8.7% YTD on price and 5.3% on NAV. The fund is increasingly venturing into tax-free munis as a way to supplan

An analyst at Guggenheim Securities turned bullish on pharma giant Bristol-Myers Squibb Co (NYSE: BMY) Monday, basing their optimism on a revival in sales of its flagship immuno-...